GURUFOCUS.COM » STOCK LIST » Latin America » Argentina » BUE » Biogen Inc (BUE:BIIB) » Definitions » Other Current Liabilities
Switch to:

Biogen (BUE:BIIB) Other Current Liabilities

: ARS36,981 Mil (As of Mar. 2023)
View and export this data going back to 2019. Start your Free Trial

Biogen's other current liabilities for the quarter that ended in Mar. 2023 was ARS36,981 Mil.

Biogen's quarterly other current liabilities increased from Sep. 2022 (ARS43,561 Mil) to Dec. 2022 (ARS66,322 Mil) but then declined from Dec. 2022 (ARS66,322 Mil) to Mar. 2023 (ARS36,981 Mil).

Biogen's annual other current liabilities declined from Dec. 2020 (ARS41,935 Mil) to Dec. 2021 (ARS34,852 Mil) but then increased from Dec. 2021 (ARS34,852 Mil) to Dec. 2022 (ARS66,322 Mil).


Biogen Other Current Liabilities Historical Data

The historical data trend for Biogen's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Other Current Liabilities
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Biogen Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Other Current Liabilities Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Biogen Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.


Biogen Other Current Liabilities Related Terms

Thank you for viewing the detailed overview of Biogen's Other Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen (BUE:BIIB) Business Description

Biogen logo
Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.

Biogen (BUE:BIIB) Headlines